The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474. doi:10.1245/s10434-010-0985-420180029
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203. doi:10.1016/j.chest.2016.10.01027780786
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 2011;12:735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:3316–3321. doi:10.1200/JCO.2010.33.375721788562
   PubMed Web of Science ®Google Scholar
• Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28:2443–2450. doi:10.1093/annonc/mdx35928945850
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun Y, Ding C, et al. China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). Ann Transl Med. 2015;3:260. doi:10.3978/j.issn.2305-5839.2015.10.3026605306
   PubMedGoogle Scholar
• Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14:953–961. doi:10.1016/S1470-2045(13)70355-323948351
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Ueda H, Shimizu R, et al. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. Clin Exp Metastasis. 2014;31:543–551. doi:10.1007/s10585-014-9648-324682604
   PubMed Web of Science ®Google Scholar
• Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-Finn C. Brain metastases from NSCLC: radiation therapy in the era of targeted therapies. J Thorac Oncol. 2016;11:1627–1643. doi:10.1016/j.jtho.2016.06.00227343440
   PubMed Web of Science ®Google Scholar
• Wu KL, Tsai MJ, Yang CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88:187–194. doi:10.1016/j.lungcan.2015.02.01225747806
   PubMed Web of Science ®Google Scholar
• Jiang T, Cheng R, Zhang G, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer. 2017;18:631–639 e632. doi:10.1016/j.cllc.2017.04.01528549835
   PubMed Web of Science ®Google Scholar
• Chang YP, Chen YM, Lai CH, et al. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS One. 2017;12:e0178676. doi:10.1371/journal.pone.017867628591157
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Tamiya A, Nakahama K, et al. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncol Lett. 2017;14:7589–7596. doi:10.3892/ol.2017.712529344206
   PubMed Web of Science ®Google Scholar
• Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y, Xiangqun S. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients. Med Oncol. 2014;31:926. doi:10.1007/s12032-014-0926-324748405
   PubMed Web of Science ®Google Scholar
• Cohen V, Agulnik JS, Ang C, et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer. 2010;116:4309–4317. doi:10.1002/cncr.2521420549828
   PubMed Web of Science ®Google Scholar
• Popper HH, Ryska A, Tímár J, Olszewski W. Molecular testing in lung cancer in the era of precision medicine. Transl Lung Cancer Res. 2014;3:291–300. doi:10.3978/j.issn.2218-6751.2014.10.0125806314
   PubMedGoogle Scholar
• Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019;367:l5460. doi:10.1136/bmj.l546031591158
   PubMed Web of Science ®Google Scholar
• Gril B, Evans L, Palmieri D, Steeg PS. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer. 2010;46:1204–1210. doi:10.1016/j.ejca.2010.02.03320303257
   PubMed Web of Science ®Google Scholar
• Shan Q, Li Z, Lin J. et al. Tumor primary location may affect metastasis pattern for patients with stage IV NSCLC: a population-based study. J Oncol;2020. 1–8. doi:10.1155/2020/4784701
   Web of Science ®Google Scholar
• Yang J, Zhang Y, Sun X, et al. The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. J Cancer Res Clin Oncol. 2018;144:1835–1842. doi:10.1007/s00432-018-2702-930003315
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhu M, Li Y, Li Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol. 2019;11:301–308. doi:10.3892/mco.2019.188131384460
   PubMed Web of Science ®Google Scholar
• Choi YW, Jeon SY, Jeong GS, et al. EGFR Exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non-small cell lung cancer patients. Am J Clin Oncol. 2018;41:385–390. doi:10.1097/COC.000000000000028226967328
   PubMed Web of Science ®Google Scholar